Is Biotest AG (BTTAY) a Buy, Sell, or Hold?
OTC : BTTAY
Biotest AG
$24.2065 USD
-$0.02 (-0.1%)
- Volume
- 0
- Average Volume
- 11
- Market Capitalization
- $942.12M
- P/E Ratio
- 48.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $24.27
- Year Low
- $22.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.06
- Current Ratio
- $5.06
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Jorg Schuttrumpf |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BTTAY |
| CUSIP | None |
| CIK | None |
| Web | https://www.biotest.com |
| Phone | 49 61 03 801 0 |
| Currency | USD |
| Employees | 2495 |
| Country | DE |
Liquidity
| Debt-to-Equity Ratio | 1.13 |
| Payout Ratio | 0.06 |
| Current Ratio | 5.06 |
| Quick Ratio | 2.06 |
| Cash Ratio | 0.67 |
Sales & Book Value
| Annual Sales | $726.2M |
| Price / Sales | 2.18 |
| Cash Flow | 0.41 |
| Price / Cash Flow | 49.19 |
| Price / Book | 2.40 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.36 |
| Trailing P/E Ratio | 48.06 |
| PEG Ratio | -0.42 |
| P/E Growth | -0.42 |
| Net Income | $26.4M |
| Net Margin | 3.64% |
| Pretax Margin | 6.40% |
| Return on Equity | 5.13% |
| Return on Assets | 1.84% |
Financials Score
| AltmanZ Score | 2.34 |
| Piotroski Score | 4.00 |
| Working Capital | 628.6M |
| Total Assets | 1.42B |
| Ebit | 7.2M |
| Market Cap | 1.65B |
| Total Liabilities | 906.9M |
Poll Results
About Biotest AG (OTC:BTTAY) Stock
Operating globally from its headquarters in Dreieich, Germany, Biotest AG is a pharmaceutical company established in 1946. It specializes in the research, development, manufacturing, and commercialization of biological medicines. The company's operations are structured across its Therapy, Plasma & Services, and Other divisions. Biotest's product portfolio addresses critical needs within hematology, clinical immunology, and intensive care medicine. For instance, Biotest provides treatments for hemophilia, including Haemoctin and Vihuma for hemophilia A, and Haemonine for hemophilia B, addressing both acute episodes and long-term prevention. Its infectious disease portfolio features therapies like Cytotect CP for cytomegalovirus, Varitect for varicella zoster virus, and several Hepatitis B-r ... elated products such as Fovepta (for neonate prophylaxis), Hepatect (reinfection prophylaxis), and Zutectra (post-liver transplant reinfection prevention). For immune system disorders and certain neurological conditions, Biotest offers Intratect and IgG Next Generation, targeting primary and secondary antibody deficiencies, and autoimmune diseases. Additionally, Biotest produces Albiomin and Biseko for plasma volume restoration, alongside Cofact and Fibrinogen to address various clotting factor deficiencies, including congenital fibrinogen deficiency. Specialized treatments further comprise Trimodulin for community-acquired pneumonia and COVID-19, and Pentaglobin for bacterial infections. Initially established as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. As of January 21, 2022, Biotest AG functions as a subsidiary of Grifols, S.A.
Frequently Asked Questions
-
What is the current Biotest AG (BTTAY) stock price?
-
Biotest AG(OTC:BTTAY) stock price is $24.2065 in the last trading session. During the trading session, BTTAY stock reached the peak price of $24.27 while $22.8 was the lowest point it dropped to. The percentage change in BTTAY stock occurred in the recent session was --0.1% while the dollar amount for the price change in BTTAY stock was -$0.02.
-
BTTAY's industry and sector of operation?
-
The OTC listed BTTAY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BTTAY?
-
Monika Buttkereit | Head of Investor Relations
Jorg Schuttrumpf | Chief Executive Officer & Chairman of Management Board
Christina Erb | Head of Corporate HR
Dirk Schuck | Employee Representative Member of Supervisory Board
| -
How many employees does BTTAY have?
-
Number of BTTAY employees currently stands at 2495. BTTAY operates from Landsteinerstrasse 5, Dreieich, None 63303, DE.
-
Link for BTTAY official website?
-
Official Website of BTTAY is: https://www.biotest.com
-
How do I contact BTTAY?
-
BTTAY could be contacted at phone #49 61 03 801 0 and can also be accessed through its website. BTTAY operates from Landsteinerstrasse 5, Dreieich, None 63303, DE.
-
How many shares of BTTAY are traded daily?
-
The average number of BTTAY shares traded daily for last 3 months was 11.
-
What is the market cap of BTTAY currently?
-
The market value of BTTAY currently stands at $942.12M with its latest stock price at $24.2065